This represents a doubling of LifeArc’s annual spend – a significant boost to the UK life sciences sector – and signals the charity’s intention to play a key role in establishing the UK as a global life sciences superpower.
The charity has been noted as an early-stage translation specialist and seeks to accelerate scientific advances in order to bring preventative processes and new diagnostics and treatments to patients more quickly.
A strategic plan drawing upon consultations with many parties – including academic researchers, industry and patient groups – will form a patient-centred, collaborative approach which will best solve the nation’s pressing health problems.
Part of the investment will be used to help emerging early-stage companies to upscale from academic settings in order to attract investors and raise further capital in the future.
